company background image
ABUS

Arbutus Biopharma NasdaqGS:ABUS Stock Report

Last Price

US$2.48

Market Cap

US$371.9m

7D

0.8%

1Y

-25.3%

Updated

16 Aug, 2022

Data

Company Financials +
ABUS fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ABUS Stock Overview

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States.

Arbutus Biopharma Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Arbutus Biopharma
Historical stock prices
Current Share PriceUS$2.48
52 Week HighUS$6.50
52 Week LowUS$1.93
Beta2.24
1 Month Change-2.36%
3 Month Change7.36%
1 Year Change-25.30%
3 Year Change69.86%
5 Year Change-32.97%
Change since IPO-64.77%

Recent News & Updates

Aug 06
Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts

Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts

Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders will have a reason to smile today, with the analysts making...

Jul 20

Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial

Arbutus Biopharma (NASDAQ:ABUS) on Wednesday said its phase 2a hepatitis B virus infection trial with partner Assembly Biosciences (ASMB) evaluating a combination involving drug candidates by both companies would continue, despite ASMB's decision to stop development of its product. ASMB in a separate release said that it would end development of its inhibitor vebicorvir. But ABUS and ASMB, after consultation, plan to continue their phase 2a trial investigating a combination of ABUS' RNAi therapeutic AB-729, ASMB's vebicorvir and an inhibitor therapy for the treatment of chronic hepatitis B virus infection. “While we respect Assembly’s decision to discontinue clinical development of (vebicorvir), we believe that it is premature to make any conclusions about any results in this triple combination clinical trial," said ABUS CEO William Collier. "We intend, in collaboration with Assembly, to continue the clinical trial in order to fully and accurately assess the results," Collier added. ABUS said preliminary data from the mid-stage trial is expected in H2 of this year. Arbutus (ABUS) stock was up 3.1% to $2.65 after hours.

Shareholder Returns

ABUSUS BiotechsUS Market
7D0.8%1.8%4.5%
1Y-25.3%-22.2%-8.9%

Return vs Industry: ABUS underperformed the US Biotechs industry which returned -19.6% over the past year.

Return vs Market: ABUS underperformed the US Market which returned -9.6% over the past year.

Price Volatility

Is ABUS's price volatile compared to industry and market?
ABUS volatility
ABUS Average Weekly Movement8.4%
Biotechs Industry Average Movement12.5%
Market Average Movement7.6%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: ABUS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: ABUS's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a86Bill Collierhttps://www.arbutusbio.com

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company’s research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19.

Arbutus Biopharma Corporation Fundamentals Summary

How do Arbutus Biopharma's earnings and revenue compare to its market cap?
ABUS fundamental statistics
Market CapUS$371.88m
Earnings (TTM)-US$76.10m
Revenue (TTM)US$33.37m

11.1x

P/S Ratio

-4.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ABUS income statement (TTM)
RevenueUS$33.37m
Cost of RevenueUS$77.33m
Gross Profit-US$43.96m
Other ExpensesUS$32.14m
Earnings-US$76.10m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.51
Gross Margin-131.73%
Net Profit Margin-228.05%
Debt/Equity Ratio0%

How did ABUS perform over the long term?

See historical performance and comparison